Global pharmaceutical company Janssen-Cilag, a subsidiary of Johnson & Johnson, has signed a three-year research collaboration agreement with Melbourne's Monash University.
The collaboration will focus on ground-breaking research at Monash University to develop potential new medicines to treat autoimmune diseases and disorders.
Professor Jamie Rossjohn, from the Department of Biochemistry and Molecular Biology at Monash University will lead the research team for the three-year project.
"Monash University offers us and our partners the world class research facilities, technology, expertise and materials that are all necessary to conduct this level of research. We are excited about the innovative therapeutic solutions that can be developed here at Monash when working with a collaborator like Janssen," Professor Rossjohn said.
Janssen-Cilag is one of the Janssen Pharmaceutical companies of Johnson & Johnson, which has its global headquarters in New Jersey, USA. It has 340 employees in Australia, and focuses on researching and developing medicines for a range of diseases which include; HIV/AIDS, arthritis, diabetes, prostate cancer and others.
Monash University, in Melbourne, is ranked in the world's top-100 universities. Its Department of Biochemistry and Molecular Biology has been ranked as the premier Department in its discipline since the inception of Australian Research Council benchmarking of Australian Departments in 1998.
News of the partnership demonstrates the strong collaborative capacity of the health industry in Melbourne and reinforces its reputation as a growing leader in global health research.
Victoria is home to 13 major independent medical research institutes, 10 teaching hospitals, nine universities and a range of clinical trial operators and contract research organisations.